Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 2
2012 2
2013 4
2015 5
2016 3
2017 4
2018 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. INSIGHT START Study Group, et al. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20. N Engl J Med. 2015. PMID: 26192873 Free PMC article. Clinical Trial.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Byonanebye DM, Polizzotto MN, Maltez F, Rauch A, Grabmeier-Pfistershammer K, Wit F, De Wit S, Castagna A, d'Arminio Monforte A, Mussini C, Wasmuth JC, Fontas E, Abela I, Sarcletti M, Bansi-Matharu L, Jaschinski N, Peters L, Hosein SR, Vannappagari V, Cohen C, Bissio E, Mocroft A, Law M, Ryom L, Petoumenos K; RESPOND study group. Byonanebye DM, et al. Among authors: bissio e. Lancet HIV. 2024 May;11(5):e321-e332. doi: 10.1016/S2352-3018(23)00328-4. Epub 2024 Apr 12. Lancet HIV. 2024. PMID: 38621392 Free PMC article.
Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.
Moragas M, Belloso WH, Baquedano MS, Gutierrez MI, Bissio E, Larriba JM, Fay F, Aulicino P, Gurevich JM, Yaunguzian MF, Maldonado AC, Falistocco C, Sen L, Mangano A. Moragas M, et al. Among authors: bissio e. Tissue Antigens. 2015 Jul;86(1):28-31. doi: 10.1111/tan.12575. Epub 2015 Apr 29. Tissue Antigens. 2015. PMID: 25922880
Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group. Pett SL, et al. HIV Med. 2018 Jan;19(1):65-71. doi: 10.1111/hiv.12532. Epub 2017 Jul 13. HIV Med. 2018. PMID: 28703491 Free article. Clinical Trial.
Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014-15.
Bissio E, Barbás MG, Bouzas MB, Cudolá A, Salomón H, Espínola L, Fernández Giuliano S, Kademián S, Mammana L, Ornani ML, Ravasi G, Vila M, Zapiola I, Falistocco C. Bissio E, et al. J Antimicrob Chemother. 2017 Feb;72(2):504-510. doi: 10.1093/jac/dkw445. Epub 2016 Oct 26. J Antimicrob Chemother. 2017. PMID: 27789684
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R; ENCORE1 Study Group. Dickinson L, et al. Clin Pharmacol Ther. 2015 Oct;98(4):406-16. doi: 10.1002/cpt.156. Epub 2015 Jul 14. Clin Pharmacol Ther. 2015. PMID: 26044067 Free PMC article. Clinical Trial.
18 results